Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Accumulated Expenses: 2019-2024

Historic Accumulated Expenses for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $38.0 million.

  • Nurix Therapeutics' Accumulated Expenses rose 57.96% to $44.0 million in Q3 2025 from the same period last year, while for Aug 2025 it was $44.0 million, marking a year-over-year increase of 57.96%. This contributed to the annual value of $38.0 million for FY2024, which is 52.16% up from last year.
  • Nurix Therapeutics' Accumulated Expenses amounted to $38.0 million in FY2024, which was up 52.16% from $25.0 million recorded in FY2023.
  • Nurix Therapeutics' 5-year Accumulated Expenses high stood at $38.0 million for FY2024, and its period low was $8.3 million during FY2020.
  • In the last 3 years, Nurix Therapeutics' Accumulated Expenses had a median value of $25.0 million in 2023 and averaged $28.5 million.
  • Data for Nurix Therapeutics' Accumulated Expenses shows a peak YoY spiked of 74.70% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Nurix Therapeutics' Accumulated Expenses stood at $8.3 million in 2020, then soared by 74.70% to $14.5 million in 2021, then surged by 54.15% to $22.4 million in 2022, then grew by 11.33% to $25.0 million in 2023, then surged by 52.16% to $38.0 million in 2024.